Valmark Advisers, Inc. Maxcyte, Inc. Transaction History
Valmark Advisers, Inc.
- $6.34 Billion
- Q3 2024
A detailed history of Valmark Advisers, Inc. transactions in Maxcyte, Inc. stock. As of the latest transaction made, Valmark Advisers, Inc. holds 113,176 shares of MXCT stock, worth $465,153. This represents 0.01% of its overall portfolio holdings.
Number of Shares
113,176
Previous 113,518
0.3%
Holding current value
$465,153
Previous $444,000
0.9%
% of portfolio
0.01%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding MXCT
# of Institutions
124Shares Held
65.6MCall Options Held
1KPut Options Held
2K-
Cadian Capital Management, LP New York, NY8.19MShares$33.7 Million1.63% of portfolio
-
Black Rock Inc. New York, NY8.14MShares$33.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.78MShares$23.7 Million0.0% of portfolio
-
Vitruvian Partners LLP5.04MShares$20.7 Million7.62% of portfolio
-
Morgan Stanley New York, NY4.82MShares$19.8 Million0.0% of portfolio
About MAXCYTE, INC.
- Ticker MXCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 101,724,000
- Market Cap $418M
- Description
- MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expr...